百利天恒首款抗体放射性核素偶联药物获批临床试验许可

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for the clinical trial of its innovative drug, Lu-177-BL-ARC001 injection, marking a significant milestone in the development of its first-in-class antibody-radionuclide conjugate (ARC) drug [1] Group 1 - The clinical trial approval for BL-ARC001 represents the company's first I-class innovative drug in the ARC field [1] - BL-ARC001 is expected to demonstrate stronger target specificity and higher tumor accumulation compared to traditional radionuclide conjugates, potentially showing better resistance to drug resistance [1] - The approval of the clinical trial application indicates a significant step forward for the company in the field of nuclear medicine research [1]